Sensydia
Sensydia Corp
Non-invasive cardiac performance system for hemodynamic assessment without catheterization.
sensydia.com · Valencia, CA
Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$8.9M of $10.9M
Filed2026-10-19
Days since filing25
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-10-05
Investors · press-matched
Form D does not name investors; these come from the matched release, as a fact with a link.
Officers on the filing
Names and roles as filed; addresses are never stored- Anthony K. ArnoldExecutive Officer · Director
- Kanav SarafExecutive Officer
- William KaiserExecutive Officer
- Rusty PageExecutive Officer
- Aman MahajanDirector
- Erick HawkinsDirector
- Victroia K. GraceDirector
- Derrick SungDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-11-13UndersubscribedNot flagged$8.9M of $10.9M sold1.3 months since first sale
Prior raiseNot flaggedRaised $8.9M against a prior $7.8M$7.8M prior raise, filed 2023-05-15
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-10-201
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- R&D Engineering InternOCT 20R&D Engineering · open 24 days
Also raised in Health & bio
Same sector, 28 days to 2026-11-15OrcosaSeries A · $6.0M of $11.5M · Ewing, NJQuietChronicleBioPre-seed · $250K of $1.0M · Menlo Park, CAQuiet
103 rounds in Health & bio in the 28 days to 2026-11-12, against 122 in the 28 days before.